The Molecular Diagnostics Laboratory offers personalized medicine through next generation sequencing assays. These assays use a patients DNA to help make a diagnosis, guide treatment, direct therapies or make a prognosis. We have two new assays available to assess solid tumors:
- Solid Tumor Precision Panel [STPP]
- The Solid Tumor Precision Panel is for assessment of molecular genetic biomarker targets for FDA-approved therapies in solid tumors. This gene panel will assess 49 genes (see below) for somatically-derived, selected hotspot mutations including single nucleotide variants [SNVs], small insertions or deletions [indels], copy number variations [CNV] and structural variants [inter-genetic and intra-genetic fusions].
- Tumor Mutational Burden (TMB) Assay [TMBO]
- The Tumor Mutation Load (TML) Assay is a targeted next-generation sequencing assay that is designed for providing an accurate assessment of TMB (mutations/Mb). Studies have shown that tumors that have a high tumor mutation burden/load (TML or TMB) potentially have a better response to immunotherapy. ?